The emergence and re-emergence of infectious diseases caused by viruses continue to be a major public health concern globally, affecting both humans and animals. One such disease is monkeypox, a zoonotic infection caused by the monkeypox virus (MPXV) that has recurred in sub-Saharan Africa over several decades. Notably, the 2022 outbreak of monkeypox in Nigeria follows a deadly outbreak in 2017, which was preceded by the disease's first recorded outbreak in 1978. Epidemiological investigations in 2017 showed no apparent link between human monkeypox cases and the outbreak that year, indicating the potential existence of multiple sources of the virus and limited human-to-human transmission. This underscores the presence of an alternative ecological niche in humans. Furthermore, in some communities in Nigeria, monkeys are regarded as sacred and not hunted or consumed, leading to their proliferation and increased likelihood of MPXV transmission. This mini-review focuses on the occurrence, epidemiological distribution, geographical distribution, endemicity, and possible solutions to reduce the spread of human monkeypox in Nigeria. The implications of this reemergence and the need for effective public health measures to prevent and control outbreaks of monkeypox are also discussed.

Monkeypox virus (MPXV), causing zoonotic diseases in humans, is a member of Orthopoxvirus under Poxviridae family. The virus was first reported in monkeys in 1959 in Denmark and in humans in 1970 in the Congo. Outside Africa, the virus first appeared in the USA in 2003 and since then occurred sporadically. The virus reemerged in 2017 and now spreading globally. African wild rodent mammals are thought to be the reservoir of MPXV. Exotic trade of animals and international travel favors the dissemination of MPXV. Genetic analysis shows two clades of the MPXV. Smallpox vaccine shows cross-protection and people who never in contact with Orthopoxvirus affected more than exposed ones. Fever, muscle pain, headache, and vesicle formation are the dominant clinical sign. Guarnieri-like inclusions and Ballooning degenerations are important pathognomic lesion of MPXV. It may produce case fatality rate up to 11%. Genetic materials alterations may favor the reemergence of the virus. The continuing occurrence over 73437 cases in 109 countries shows that MPXV can spread among humans competently and can be a serious issue of global public health concern. Here, we summarize the existing knowledge about re-emergence and insights into MPXV which will be of useful to curb its occurrence.

Background: While mankind is still dealing with the COVID-19 pandemic, on May 7, 2022, a case of monkeypox virus (MPXV) has been reported to the WHO. Monkeypox is a viral zoonotic disease with characteristics comparable to those seen in smallpox cases in the past. It has been a public health threat, particularly in Africa, but recently have been circulating the world, consequently, may become a global public health threat in a very short period. Thus, the current work was planned and then constructed a multi-epitope vaccine that can evoke an immunological response against MPXV utilizing cell surface-binding protein as a target in order to develop a novel vaccine that is both safe and almost free of side effects. Results: The proposed vaccine composed of 304 amino acids and was shown to be antigenic in Vaxijen server (0. 5311) and nonallergenic in AllerTop server. The 3D structure of the designed vaccine is predicted, refined and validated by various in silico tools to assess the stability of the vaccine. Moreover, solubility of the vaccine construct was found greater than the average solubility provided by protein-Sol server indicating the solubility of the vaccine construct. Moreover, the most promising epitopes bound to MHC I and MHC II alleles were found having good binding affinities with low energies ranging between ₋7.0 - ₋8.1kcal/mol. Conclusion: We conclude from our research that the cell surface-binding protein is one of the primary proteins involved in MPXV pathogenesis. The most promising epitopes were selected using a rigorous procedure and used for vaccine design. As a result, our study will aid in the development of appropriate therapeutics and prompt the development of future vaccines against MPXV, which could serve as an important milestone in the production of an antiviral vaccine against MPXV.